They are designed to improve the body’s ability to decrease blood sugar when it is elevated by functioning on the organic hormones, incretins, thereby increasing insulin production, and by reducing the liver’s creation of glucose. The release of ONGLYZA is likely to begin in the fourth quarter of 2009.. Bristol-Myers AstraZeneca and Squibb receive advertising authorisation for ONGLYZA in Europe Bristol-Myers Squibb Firm and AstraZeneca announced today that the European Commission has granted marketing authorisation for ONGLYZATM in the 27 countries of the European Union. ONGLYZA can be indicated as a once-daily 5 mg oral tablet dosage in adult individuals with type 2 diabetes mellitus to improve glycaemic control: in conjunction with metformin, when metformin only, with diet and exercise, does not provide adequate glycaemic control; in combination with a sulphonylurea, when sulphonylurea only, with diet and exercise, does not provide sufficient glycaemic control in individuals for whom use of metformin is considered inappropriate; or in conjunction with a thiazolidinedione, when the thiazolidinedione only, with diet and exercise, does not provide adequate glycaemic control in individuals for whom usage of a thiazolidinedione is known as appropriate.Research collaborators consist of Huong T. Perform, M.A., and Andrew W. Dick, Ph.D., senior economist at the RAND Corporation in Pittsburgh, Pa. The analysis is structured on an assessment of women aged 65 and older diagnosed with either DCIS or Stage 1 breast tumor from 1991 to 1999 and followed through 2002 in registries of the Surveillance, Epidemiology, and FINAL RESULTS System sponsored by the National Cancer tumor Institute. This representative nationally, population-based study of older women provided a distinctive opportunity to research the consequences of suboptimal treatment in the community setting.